Premium
Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
Author(s) -
Carol Hernan,
Reynolds C. Patrick,
Kang Min H.,
Keir Stephen T.,
Maris John M.,
Gorlick Richard,
Kolb E. Anders,
Billups Catherine A.,
Geier Brian,
Kurmasheva Raushan T.,
Houghton Peter J.,
Smith Malcolm A.,
Lock Richard B.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24235
Subject(s) - rhabdomyosarcoma , medulloblastoma , medicine , in vivo , wilms' tumor , sarcoma , mdm2 , pediatric cancer , cancer research , apoptosis , cancer , pathology , biology , biochemistry , microbiology and biotechnology
RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively low incidence of p53 mutations in pediatric cancers compared with adult malignancies.